{"id":31519,"date":"2025-04-22T16:42:39","date_gmt":"2025-04-22T11:12:39","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31519"},"modified":"2025-05-01T16:29:07","modified_gmt":"2025-05-01T10:59:07","slug":"pharma-news-for-regeneron-gilead-neuronos","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos","title":{"rendered":"FDA Approves Sanofi\/Regeneron\u2019s DUPIXENT as First New CSU Therapy in Over a Decade; Gilead\u2019s TRODELVY + KEYTRUDA Shows PFS Benefit in PD-L1+ TNBC; Tempest\u2019s TPST-1495 Gets FDA Orphan Tag for FAP; uniQure\u2019s AMT-130 Granted FDA Breakthrough for Huntington\u2019s; NeuroNOS\u2019 BA-102 Secures FDA Orphan Status for Phelan-McDermid Syndrome"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f4e2899fb05\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f4e2899fb05\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos\/#FDA_Approves_SanofiRegenerons_DUPIXENT_as_First_New_Targeted_Therapy_in_Over_a_Decade_for_Chronic_Spontaneous_Urticaria\" >FDA Approves Sanofi\/Regeneron\u2019s DUPIXENT as First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos\/#Gileads_TRODELVY_Plus_KEYTRUDA_Shows_Significant_Benefit_in_PD-L1_Metastatic_TNBC\" >Gilead\u2019s TRODELVY Plus KEYTRUDA Shows Significant Benefit in PD-L1+ Metastatic TNBC<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos\/#Tempest_Secures_FDA_Orphan_Drug_Designation_for_TPST-1495_in_FAP\" >Tempest Secures FDA Orphan Drug Designation for TPST-1495 in FAP<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos\/#uniQures_AMT-130_Receives_FDA_Breakthrough_Therapy_Designation_for_Huntingtons_Disease\" >uniQure\u2019s AMT-130 Receives FDA Breakthrough Therapy Designation for Huntington\u2019s Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos\/#NeuroNOS_BA-102_Granted_FDA_Orphan_Drug_Designation_for_Phelan-McDermid_Syndrome\" >NeuroNOS\u2019 BA-102 Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-sanofi-regeneron-s-dupixent-as-first-new-targeted-therapy-in-over-a-decade-for-chronic-spontaneous-urticaria\"><span class=\"ez-toc-section\" id=\"FDA_Approves_SanofiRegenerons_DUPIXENT_as_First_New_Targeted_Therapy_in_Over_a_Decade_for_Chronic_Spontaneous_Urticaria\"><\/span>FDA Approves Sanofi\/Regeneron\u2019s DUPIXENT as First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Regeneron Pharmaceuticals and Sanofi<\/strong> have announced that the <strong>FDA <\/strong>has <strong>approved DUPIXENT (dupilumab) <\/strong>for the <strong>treatment <\/strong>of <strong>adults and adolescents<\/strong> aged 12 years and older with <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-spontaneous-urticaria-market\"><strong>chronic spontaneous urticaria (CSU)<\/strong><\/a> who remain symptomatic despite treatment with histamine-1 (H1) antihistamines. This approval marks the first new targeted therapy for CSU in over a decade. The decision is based on the results of <strong>two Phase III trials,<\/strong> which showed that DUPIXENT significantly reduced itch severity and urticaria activity when used in combination with antihistamines, compared to antihistamines alone.<\/p>\n\n\n\n<p><em>\u201cPeople with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives,\u201d said Kenneth Mendez, President and CEO of the Asthma and Allergy Foundation of America. \u201cThe approval of this treatment offers patients more options and the chance to control their disease.\u201d<\/em><\/p>\n\n\n\n<p>DUPIXENT has now been approved in multiple regions, including Japan, the UAE, and Brazil. It is expected to provide a new, effective option for over 300,000 patients in the U.S. with CSU that remains inadequately controlled on standard treatments. The clinical trials demonstrated DUPIXENT\u2019s ability to increase the likelihood of well-controlled disease or complete response after 24 weeks of treatment.<\/p>\n\n\n\n<p><em>\u201cDUPIXENT is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over ten years, with pivotal trials demonstrating its ability to help patients significantly reduce the hallmark symptoms of intense itch and unpredictable hives associated with this disease,\u201d said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron.<\/em><\/p>\n\n\n\n<p><em>The approval provides a much-needed option for patients who struggle with the chronic nature of CSU and often experience debilitating symptoms. Alyssa Johnsen, M.D., Ph.D., Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi, emphasized, \u201cCSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms.\u201d<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gilead-s-trodelvy-plus-keytruda-shows-significant-benefit-in-pd-l1-metastatic-tnbc\"><span class=\"ez-toc-section\" id=\"Gileads_TRODELVY_Plus_KEYTRUDA_Shows_Significant_Benefit_in_PD-L1_Metastatic_TNBC\"><\/span>Gilead\u2019s TRODELVY Plus KEYTRUDA Shows Significant Benefit in PD-L1+ Metastatic TNBC<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Gilead Sciences<\/strong> has announced positive results from the <strong>Phase III ASCENT-04\/KEYNOTE-D19 study,<\/strong> showing that the combination of <strong>TRODELVY (sacituzumab govitecan-hziy) and KEYTRUDA (pembrolizumab)<\/strong> significantly improves progression-free survival (PFS) in patients with inoperable <a href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-market\"><strong>locally advanced or metastatic triple-negative breast cancer (mTNBC)<\/strong><\/a> whose tumors express PD-L1 (CPS \u2265 10). The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in PFS compared to KEYTRUDA and chemotherapy.<\/p>\n\n\n\n<p><em>\u201cThese findings are the first to show the transformative potential of an antibody-drug conjugate combined with an immuno-oncology agent in early treatment lines of metastatic breast cancer,\u201d said Dietmar Berger, MD, PhD, Chief Medical Officer at Gilead Sciences. \u201cFor patients with this difficult-to-treat type of breast cancer, these results potentially offer a new pathway that may redefine their treatment options.\u201d<\/em><\/p>\n\n\n\n<p>The safety profile of TRODELVY plus KEYTRUDA was consistent with the known safety profiles of each drug, and no new safety signals were identified. An early trend toward improved overall survival (OS) was observed, though OS data was not mature at the time of the PFS analysis. Gilead plans to continue monitoring OS outcomes and conduct further analyses.<\/p>\n\n\n\n<p><em>\u201cFor patients with metastatic triple-negative breast cancer, there is a critical need for more effective treatment options,\u201d said Dr. Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute and primary investigator of the study. \u201cThese data suggest that the combination of sacituzumab govitecan-hziy and pembrolizumab may offer a new treatment approach\u2014bringing together a potent antibody drug conjugate with immunotherapy to improve outcomes for patients.\u201d<\/em><\/p>\n\n\n\n<p>TRODELVY has already demonstrated survival advantages in two types of metastatic breast cancer, and it continues to show consistent results across multiple studies. Gilead is conducting further research into TRODELVY\u2019s efficacy in various tumor types and disease stages, including ongoing Phase III trials for other breast cancer subtypes and additional cancers.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-tempest-secures-fda-orphan-drug-designation-for-tpst-1495-in-fap\"><span class=\"ez-toc-section\" id=\"Tempest_Secures_FDA_Orphan_Drug_Designation_for_TPST-1495_in_FAP\"><\/span>Tempest Secures FDA Orphan Drug Designation for TPST-1495 in FAP<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Tempest Therapeutics <\/strong>has announced that the <strong>FDA <\/strong>has granted <strong>Orphan Drug Designation (ODD)<\/strong> to <strong>TPST-1495<\/strong>, a novel dual receptor<strong> inhibitor targeting prostaglandin (PGE2)<\/strong> signaling, for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/familial-adenomatous-polyposis-market\"><strong>Familial Adenomatous Polyposis (FAP)<\/strong><\/a>. This milestone marks a significant advancement in Tempest&#8217;s mission to develop innovative therapies for cancers with unmet medical needs.<\/p>\n\n\n\n<p><em>\u201cReceiving orphan drug designation for TPST-1495, our second clinical program, is a significant milestone in our mission to bring innovative therapies to patients with unmet medical need,\u201d said Stephen Brady, President and CEO of Tempest. \u201cThis designation for the treatment of FAP underscores Tempest\u2019s mission to make a meaningful difference in the lives of patients and builds on the momentum from prior designations received for amezalpat in hepatocellular carcinoma.\u201d<\/em><\/p>\n\n\n\n<p>Tempest is set to begin a Phase II study evaluating TPST-1495 in FAP patients later this year, funded by the National Cancer Institute (NCI) Division of Cancer Prevention and conducted by the Cancer Prevention Clinical Trials Network. Data from the study are expected in 2026.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-uniqure-s-amt-130-receives-fda-breakthrough-therapy-designation-for-huntington-s-disease\"><span class=\"ez-toc-section\" id=\"uniQures_AMT-130_Receives_FDA_Breakthrough_Therapy_Designation_for_Huntingtons_Disease\"><\/span>uniQure\u2019s AMT-130 Receives FDA Breakthrough Therapy Designation for Huntington\u2019s Disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>uniQure <\/strong>has announced that the <strong>FDA <\/strong>has granted <strong>Breakthrough Therapy designation<\/strong> to <strong>AMT-130<\/strong> for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-market\"><strong>Huntington\u2019s disease<\/strong><\/a>, a rare and inherited neurodegenerative disorder with no current disease-modifying therapies. This designation complements the previously granted <strong>Regenerative Medicine Advanced Therapy (RMAT),<\/strong> <strong>Orphan Drug, and Fast Track designations for AMT-130.<\/strong><\/p>\n\n\n\n<p><em>\u201cReceiving Breakthrough Therapy designation underscores both the urgent need for effective treatments for Huntington\u2019s disease and the encouraging interim data demonstrating that AMT-130 has the potential to slow disease progression,\u201d said Walid Abi-Saab, M.D., Chief Medical Officer of uniQure. \u201cIt\u2019s a powerful recognition of the promise of AMT-130 and the important progress we\u2019ve made. We deeply value the FDA\u2019s continued commitment to advancing innovative gene therapies for patients with critical unmet needs, and we look forward to working closely with the agency to bring AMT-130 to the Huntington\u2019s disease patient community as quickly as possible.\u201d<\/em><\/p>\n\n\n\n<p>The Breakthrough Therapy designation is based on clinical data from the ongoing Phase I\/II trials of AMT-130. In July 2024, interim data revealed a dose-dependent slowing of disease progression in treated patients compared to natural history controls. To date, 45 patients have received AMT-130. This designation allows for expedited development and review, providing uniQure with increased support and guidance from the FDA.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-neuronos-ba-102-granted-fda-orphan-drug-designation-for-phelan-mcdermid-syndrome\"><span class=\"ez-toc-section\" id=\"NeuroNOS_BA-102_Granted_FDA_Orphan_Drug_Designation_for_Phelan-McDermid_Syndrome\"><\/span>NeuroNOS\u2019 BA-102 Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>NeuroNOS,<\/strong> a biopharmaceutical company focused on treatments for <strong>autism <\/strong>and <strong>Alzheimer&#8217;s disorders,<\/strong> has announced that the <strong>FDA <\/strong>has granted <strong>Orphan Drug Designation (ODD) <\/strong>to its lead investigational therapy, <strong>BA-102,<\/strong> for <strong>Phelan-McDermid Syndrome (PMS),<\/strong> a genetic disorder associated with <a href=\"https:\/\/www.delveinsight.com\/report-store\/autism-spectrum-disorder-asd-market\"><strong>Autism Spectrum Disorder (ASD)<\/strong><\/a>. The company plans to begin first-in-human clinical trials for ASD in the United States in 2026.<\/p>\n\n\n\n<p><em>\u201cReceiving orphan drug designation from the FDA is a significant step forward for this autism program, as well as our broader mission to bring targeted therapies to individuals and families affected by rare neurodevelopmental conditions,\u201d said Amir Avniel, CEO of NeuroNOS. \u201cBy focusing on the genetic underpinnings of Phelan-McDermid Syndrome\u2014a syndromic form of autism\u2014we aim to address the root cause of symptoms and offer new hope where few options currently exist.\u201d<\/em><\/p>\n\n\n\n<p>PMS is caused by deletions or mutations of the SHANK3 gene, leading to developmental delays, intellectual disability, severe speech impairments, and often features of ASD. Currently, no FDA-approved treatments are specifically indicated for PMS. The Orphan Drug Designation offers key development incentives, including market exclusivity upon approval and access to FDA support.<\/p>\n\n\n\n<p><em>\u201cPhelan-McDermid Syndrome represents a critical unmet medical need,\u201d said Prof. Haitham Amal, CSO of NeuroNOS. \u201cWe are committed to working closely with the FDA, patient advocacy groups, scientific foundations, and clinical investigators to accelerate development of a therapy that could meaningfully improve quality of life for those living with this challenging genetic condition.\u201d<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA Approves Sanofi\/Regeneron\u2019s DUPIXENT as First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria Regeneron Pharmaceuticals and Sanofi have announced that the FDA has approved DUPIXENT (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite treatment with histamine-1 (H1) [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":31520,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[3038,19119,21183,21181,777,17448,704,305,12745,349,18214,420,639,5789,2012],"industry":[17225],"therapeutic_areas":[17237,17238,17228],"class_list":["post-31519","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-autism-spectrum-disorder","tag-chronic-spontaneous-urticaria","tag-chronic-spontaneous-urticaria-market","tag-chronic-spontaneous-urticaria-therapies","tag-familial-adenomatous-polyposis","tag-familial-adenomatous-polyposis-market","tag-fda","tag-huntingtons-disease","tag-huntingtons-disease-market","tag-latest-pharma-news","tag-metastatic-triple-negative-breast-cancer","tag-news","tag-pharma-news","tag-recent-pharma-news","tag-triple-negative-breast-cancer","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-genetic-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Regeneron, Gilead, NeuroNOS<\/title>\n<meta name=\"description\" content=\"Sanofi\/Regeneron\u2019s DUPIXENT, Gilead\u2019s TRODELVY + KEYTRUDA, Tempest\u2019s TPST-1495, uniQure\u2019s AMT-130, NeuroNOS\u2019 BA-102 Orphan Drug\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Regeneron, Gilead, NeuroNOS\" \/>\n<meta property=\"og:description\" content=\"Sanofi\/Regeneron\u2019s DUPIXENT, Gilead\u2019s TRODELVY + KEYTRUDA, Tempest\u2019s TPST-1495, uniQure\u2019s AMT-130, NeuroNOS\u2019 BA-102 Orphan Drug\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-22T11:12:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-01T10:59:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/22164155\/22-04-2025.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Regeneron, Gilead, NeuroNOS","description":"Sanofi\/Regeneron\u2019s DUPIXENT, Gilead\u2019s TRODELVY + KEYTRUDA, Tempest\u2019s TPST-1495, uniQure\u2019s AMT-130, NeuroNOS\u2019 BA-102 Orphan Drug","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Regeneron, Gilead, NeuroNOS","og_description":"Sanofi\/Regeneron\u2019s DUPIXENT, Gilead\u2019s TRODELVY + KEYTRUDA, Tempest\u2019s TPST-1495, uniQure\u2019s AMT-130, NeuroNOS\u2019 BA-102 Orphan Drug","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-04-22T11:12:39+00:00","article_modified_time":"2025-05-01T10:59:07+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/22164155\/22-04-2025.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos","name":"Pharma News | Regeneron, Gilead, NeuroNOS","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/22164155\/22-04-2025.png","datePublished":"2025-04-22T11:12:39+00:00","dateModified":"2025-05-01T10:59:07+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Sanofi\/Regeneron\u2019s DUPIXENT, Gilead\u2019s TRODELVY + KEYTRUDA, Tempest\u2019s TPST-1495, uniQure\u2019s AMT-130, NeuroNOS\u2019 BA-102 Orphan Drug","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-gilead-neuronos#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/22164155\/22-04-2025.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/22164155\/22-04-2025.png","width":772,"height":482,"caption":"pharma-news-for-regeneron-gilead-neuronos"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/22164155\/22-04-2025-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">autism spectrum disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic Spontaneous Urticaria<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">chronic spontaneous urticaria market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">chronic spontaneous urticaria therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Familial Adenomatous Polyposis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Familial Adenomatous Polyposis Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Huntington\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Huntington\u2019s disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Metastatic Triple Negative Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">TRIPLE NEGATIVE BREAST CANCER<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">autism spectrum disorder<\/span>","<span class=\"advgb-post-tax-term\">Chronic Spontaneous Urticaria<\/span>","<span class=\"advgb-post-tax-term\">chronic spontaneous urticaria market<\/span>","<span class=\"advgb-post-tax-term\">chronic spontaneous urticaria therapies<\/span>","<span class=\"advgb-post-tax-term\">Familial Adenomatous Polyposis<\/span>","<span class=\"advgb-post-tax-term\">Familial Adenomatous Polyposis Market<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u2019s disease Market<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Metastatic Triple Negative Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">TRIPLE NEGATIVE BREAST CANCER<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Apr 22, 2025","modified":"Updated on May 1, 2025"},"absolute_dates_time":{"created":"Posted on Apr 22, 2025 4:42 pm","modified":"Updated on May 1, 2025 4:29 pm"},"featured_img_caption":"pharma-news-for-regeneron-gilead-neuronos\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31519"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31519\/revisions"}],"predecessor-version":[{"id":31521,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31519\/revisions\/31521"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31520"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31519"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31519"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}